My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Allocation Agreement with exhibits - final
>
Meetings
>
2022
>
09. September
>
2022-09-06 10:00 AM - Commissioners' Agenda
>
Allocation Agreement with exhibits - final
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
9/1/2022 1:11:41 PM
Creation date
9/1/2022 1:10:08 PM
Metadata
Fields
Template:
Meeting
Date
9/6/2022
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Authorizing the Chair's Signature on a Opioid Litigation Allocation Agreement
Order
3
Placement
Consent Agenda
Row ID
93293
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
106
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
9 <br />address mental health needs in young people that (when not properly addressed) <br />increase the risk of opioid or other drug misuse. <br />H.PREVENT OVERDOSE DEATHS AND OTHER HARMS <br />Support efforts to prevent or reduce overdose deaths or other opioid-related harms through <br />evidence-based, evidence-informed, or promising programs or strategies that may include, <br />but are not limited to, the following: <br />1.Increase availability and distribution of naloxone and other drugs that treat overdoses <br />for first responders, overdose patients, opioid users, families and friends of opioid <br />users, schools, community navigators and outreach workers, drug offenders upon <br />release from jail/prison, or other members of the general public. <br />2.Provision by public health entities of free naloxone to anyone in the community, <br />including but not limited to provision of intra-nasal naloxone in settings where other <br />options are not available or allowed. <br />3.Training and education regarding naloxone and other drugs that treat overdoses for <br />first responders, overdose patients, patients taking opioids, families, schools, and <br />other members of the general public. <br />4.Enable school nurses and other school staff to respond to opioid overdoses, and <br />provide them with naloxone, training, and support. <br />5.Expand, improve, or develop data tracking software and applications for <br />overdoses/naloxone revivals. <br />6.Public education relating to emergency responses to overdoses. <br />7.Public education relating to immunity and Good Samaritan laws. <br />8.Educate first responders regarding the existence and operation of immunity and Good <br />Samaritan laws. <br />9.Expand access to testing and treatment for infectious diseases such as HIV and <br />Hepatitis C resulting from intravenous opioid use. <br />10.Support mobile units that offer or provide referrals to treatment, recovery supports, <br />health care, or other appropriate services to persons that use opioids or persons with <br />OUD and any co-occurring SUD/MH conditions, co-usage, and/or co-addiction. <br />11.Provide training in treatment and recovery strategies to health care providers, <br />students, peer recovery coaches, recovery outreach specialists, or other professionals <br />that provide care to persons who use opioids or persons with OUD and any co- <br />occurring SUD/MH conditions, co-usage, and/or co-addiction. <br />12.Support screening for fentanyl in routine clinical toxicology testing.
The URL can be used to link to this page
Your browser does not support the video tag.